News ReleaseView printer-friendly version
Quidel First Quarter 2004 Results Conference Call Alert
SAN DIEGO, Calif.--(BUSINESS WIRE)--April 14, 2004--Quidel Corporation (Nasdaq:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, will release first quarter 2004 financial results after market close on Wednesday, April 28, 2004, at 4:10 p.m. ET (1:10 p.m. PT).
S. Wayne Kay, president and chief executive officer, and Paul E. Landers, senior vice president and chief financial officer, will be hosting an investment community conference call beginning at 5:00 p.m. ET (2:00 p.m. PT) on Wednesday, April 28, 2004, to discuss those results and to answer questions.
To participate in the live call by telephone, please dial 888-803-7396 from the U.S., or for international callers, please dial 706-634-1052.
Those interested in listening to the conference call live via the Internet may do so by visiting the Company's Web site at www.quidel.com. To listen to the live call, please go to the Web site 15 minutes prior to its start to register, download and install the necessary audio software.
A replay will be available on Quidel's Web site for 14 days. A telephone replay will be available for 48 hours by dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers, and entering reservation number 5211939.
Quidel Corporation is a global company dedicated to helping women and their families live healthy lives through the discovery, development, manufacture and marketing of rapid point-of-care (POC) diagnostic tests. These tests detect medical conditions and illnesses associated with women's health in areas such as reproduction and diseases of the elderly. Quidel also provides POC diagnostic tests for infectious diseases, including influenza A & B, Strep throat, H. pylori infection, Chlamydia, infectious mononucleosis and infectious vaginitis. Quidel's diagnostic tests provide information that results in rapid treatment, improved health outcomes, lowered costs and increased patient satisfaction. Quidel's products are sold for use in physician offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label products. For more information visit www.quidel.com
CONTACT: Quidel Corporation
Paul E. Landers, 858-552-7962
Lippert/Heilshorn & Associates
Ina McGuinness (email@example.com)
Bruce Voss (firstname.lastname@example.org)
SOURCE: Quidel Corporation